Fewer people on newer diabetes drugs got thyroid eye disease, study finds

Some people with an overactive thyroid, a gland in the neck that has started working too hard, notice their eyes changing. The eyes turn red and puffy and seem to bulge, and some people start seeing double. This is thyroid eye disease. The body's defenses attack the soft tissue behind the eyes, which swells and pushes the eyeballs forward [1].

A large study of health records has now found that people with thyroid disease who started a newer kind of blood sugar drug got this eye disease less often. In the first year it was found about 18 percent less often than in people starting other blood sugar drugs. Surgeries for it were about 58 percent lower [1].

The main caveat comes first. This study looked back at records, so it can show a link but not a cause. Nobody was put on a drug for the research. Doctors chose who got what, and their reasons are not always written down [1].

The drugs are GLP-1 medicines, which copy a hormone the gut releases after a meal. The study was led by Jawad Muayad of the Texas A&M University College of Medicine. It was published in 2026 in Ophthalmic Plastic and Reconstructive Surgery, a journal for eye surgeons [1].

How was the study done?

The team searched a network of hospital records in the United States for people with thyroid disease who were starting a blood sugar drug. Some started a GLP-1 drug and some started a different kind. Each person was then paired with someone from the other group who was alike in age, sex, weight, blood sugar, other illnesses and thyroid test results. That left 173,618 people in each group [1].

The eye disease was found less often in the GLP-1 group at every check: about 18 percent less at one year, 14 percent at two years and 10 percent at three. Surgeries were still about 46 percent lower at three years. Strong steroid medicines, which calm swelling, were used less as well. The same pattern held in people with an overactive thyroid and for single drugs, not just the whole group [1][2].

The researchers chose their words with care:

These findings suggest a potential protective role for GLP-1 signaling in modulating orbital inflammation, though prospective trials are required for confirmation.

Muayad and colleagues, Ophthalmic Plastic and Reconstructive Surgery, 2026 [1]

In plain words, the drugs may help calm swelling around the eyes. Only a trial that puts people on a treatment from the start can confirm it. Matching evens out the groups only on what the records held. It cannot fix anything the records left out. And everyone in the study had thyroid disease and was starting a blood sugar drug, so the results do not carry over to anyone else [1].

What about the thyroid warning on these drugs?

In the United States, the label on semaglutide, one of these drugs, carries a boxed warning, the most serious kind a label can have. Rats and mice given the drug for their whole lives grew more tumors in one kind of thyroid cell, and more so at higher amounts. The label says it is not known whether this happens in people. It also says the drug must never be given to people who have had medullary thyroid cancer, a rare kind of thyroid cancer, or whose close relatives have had it. The same goes for MEN 2, a condition passed down in families [5].

Two large national studies have looked for a thyroid cancer link in people and reached opposite answers. A study in France found more thyroid cancer in people with type 2 diabetes who had used these drugs for one to three years [6]. A bigger study across Denmark, Norway and Sweden compared 145,410 new users with 291,667 people starting a different drug and found no clear rise [7]. Its authors wrote:

In this large cohort study using nationwide data from three countries, GLP1 receptor agonist use was not associated with a substantially increased risk of thyroid cancer over a mean follow-up of 3.9 years.

Scandinavian cohort study, BMJ, 2024 [7]

In plain words, over about four years, people on these drugs did not get clearly more thyroid cancer. Part of the disagreement may come from how often people are checked. Someone who just started a new drug tends to see a doctor more, so more small cancers may be found, even if there are not more of them [6][7].

Other work is at an earlier stage. A 2026 review found that trials made just for autoimmune thyroid disease, where the body attacks its own thyroid, are still missing [3]. A team in Mainz, Germany, worked with mice that had a form of Graves' disease, an illness that makes the thyroid overactive. They treated the mice with a different molecule, a small ring shaped peptide. The mice improved, but only some animal results carry over to people [4].

Put together, the records study does not show that GLP-1 drugs protect the eyes. It shows a link worth testing in a proper trial, and the label warning remains a question the national studies have not settled. What it does show is that, in hundreds of thousands of matched patients, the eye disease and its surgeries were found less often on these drugs [1][3][6][7].